31 research outputs found
Erratum: Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC) (Pediatr Rheumatol Online J (2019) 17 (66) DOI: 10.1186/s12969-019-0345-2)
No full textFollowing publication of the original article [1], we have been notified that the author Joan Calzada should not have been included to the team of authors. The authors' team, thus, should be as follows: Ivan Foeldvari1*, Jens Klotsche2,3, Gabriele Simonini4, Clive Edelsten5, Sheila T. Angeles-Han6, Regitze Bangsgaard7, Joke de Boer8, Gabriele Brumm9, Rosa Bou Torrent10,21, Tamas Constantin11, Cinzia DeLibero12, Jesus Diaz23,24,Valeria Maria Gerloni13, Margarida Guedes14, Arnd Heiligenhaus15, Kaisu Kotaniemi16, Sanna Leinonen16, Kirsten Minden2,17, Vasco Miranda18, Elisabetta Miserocchi19, Susan Nielsen7, Martina Niewerth2, Irene Pontikaki13,Carmen Garcia de Vicuna10, Carla Zilhao14, Steven Yeh20, Jordi Anton10,21,2
Epstein-Barr virus dacryoadenitis as a complication of bone marrow transplant in a child with combined immunodeficiency
No full textFactors related to severe uveitis at diagnosis in children with juvenile idiopathic arthritis in a screening program
No full textConsensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis:the SHARE initiative
No full textBACKGROUND: In 2012, a European initiative called Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases. Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and uveitis is possibly its most devastating extra-articular manifestation. Evidence-based guidelines are sparse and management is mostly based on physicians' experience. Consequently, treatment practices differ widely, within and between nations.OBJECTIVES: To provide recommendations for the diagnosis and treatment of JIA-associated uveitis.METHODS: Recommendations were developed by an evidence-informed consensus process using the European League Against Rheumatism standard operating procedures. A committee was constituted, consisting of nine experienced paediatric rheumatologists and three experts in ophthalmology from Europe. Recommendations derived from a validated systematic literature review were evaluated by an Expert Committee and subsequently discussed at two consensus meetings using nominal group techniques. Recommendations were accepted if >80% agreement was reached (including all three ophthalmologists).RESULTS: In total, 22 recommendations were accepted (with >80% agreement among experts): 3 on diagnosis, 5 on disease activity measurements, 12 on treatment and 2 on future recommendations.CONCLUSIONS: The SHARE initiative aims to identify best practices for treatment of patients suffering from JIA-associated uveitis. Within this remit, recommendations for the diagnosis and treatment of JIA-associated uveitis have been formulated by an evidence-informed consensus process to suggest a standard of care for JIA-associated uveitis patients throughout Europe.</p
Possession of the HLA-DRB1*1501 Allele and Visual Outcome in Idiopathic Intermediate Uveitis
No full textIdiopathic intermediate uveitis (IIU) is a potentially sight-threatening inflammatory disease characterized by breakdown of the blood-retina barrier with consequent leukocytic infiltration of the vitreous and retina. Poor visual outcome has been associated with cystoid macular edema, poor vision at presentation, and male sex.1 The human leukocyte antigen (HLA) allele DRB1*1501 has long been associated with multiple sclerosis (MS). Tang et al2 prospectively analyzed 18 patients and found that HLA-DRB1*1501 conferred increased risk of developing IIU associated with MS in some patients.The purposes of this study were to prospectively evaluate the association between the HLA-DRB1*1501 allele and IIU in patients and to determine whether HLA-DRB1*1501 might be a separate independent risk factor for visual loss
